Here are the four latest drugs or medical devices approved by the Food and Drug Administration this week.
- Actemra may now be used to treat adults with giant cell arteritis — a chronic and potentially fatal autoimmune condition caused by inflammation of large and medium-sized arteries in the head or aorta.
- The Flourish Pediatric Esophageal Atresia device treats infants with esophageal atresia, a birth defect where the upper esophagus does not connect to the lower half of the esophagus and stomach.
- Kevzara is a biologic drug intended to treat patients with moderate to severe rheumatoid arthritis who do not respond to other treatments.
- Keytruda may now be used to treat solid cancer tumors that are inoperable or that have metastasized in patients with specific genetic biomarkers.
More articles on supply chain:
Ex-Heritage Pharma execs settle national price fixing lawsuit: 4 things to know
FDA on track to surpass total new drug approvals from 2016
6 must-reads for supply chain leaders this week